Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2009

GenoLogics and CLC bio to Provide Data-Management and Analysis Solution for Next-Gen Sequencing

  • GenoLogics and CLC bio are combining their technologies to provide clients with an end-to-end informatics and analysis solution for next-generation sequencing. The new tool will offer a unified environment for both laboratory/data management and data anlaysis by coupling GenoLogics’ Geneus lab and data-management system for genomics with CLC bio’s CLC Genomics Server, CLC Genomic Workbench, and CLC NGS Cell platforms.

    The companies claim that this solution will improve researchers’ ability to aggregate raw data across NGS experiments, from initial sample submission to final analysis. “This way,” notes Thomas Knudsen, CEO at CLC bio, “researchers can keep up with the vast volumes of sequencing data being churned out by high-throughput sequencing machines and quickly turn the massive amounts of raw data into meaningful results.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »